ClinicalTrials.Veeva

Menu

Fluid Restriction in Patients With Heart Failure

H

Hospital de Clinicas de Porto Alegre

Status

Unknown

Conditions

Heart Failure, Systolic
Heart Failure; With Decompensation
Pulmonary Congestion

Treatments

Behavioral: Fluid restriction

Study type

Interventional

Funder types

Other

Identifiers

NCT04611594
HCPA 2019-0216

Details and patient eligibility

About

There is a concept increasingly consolidated by clinical evidence that at each hospitalization due to HF decompensation there is a substantial loss of quality of life, which is associated with an initial period of great clinical vulnerability, with high rates of rehospitalization and an increased risk of death. The non-pharmacological measures that are widely practiced and recommended for HF patients, such as fluid restriction, specially at the first 30 days after hospital discharge, still lack clearer evidence of their therapeutic efficacy.

Full description

The need for hospitalization is an important marker of poor prognosis in patients with heart failure. It is estimated that 25% of patients presenting with acute heart failure are readmitted within 30 days. The maintenance of signs and symptoms of congestion at hospital discharge are common causes of hospital readmission. Thus, the reduction of these signs is a goal to be reached during hospitalization so that the chances of readmission are reduced. However, there is evidence that approximately ¼ of the patients are released despite persisting signs of congestive symptoms. It seems plausible to speculate that patients with HF at higher risk of rehospitalization would be those with the greatest chance of benefiting from therapeutic strategies that seek to reduce the congestive state, such as fluid restriction. In this scenario of initial vulnerability after hospitalization for acutely decompensated HF, recent studies have demonstrated a correlation in the number of B lines in the pulmonary ultrasound of patients at the time of hospital discharge and the prediction of frequent clinical outcomes. It was observed that the presence of pattern B, defined as the presence of more than 3 B lines in at least 2 pulmonary fields bilaterally, was associated with a worse prognosis (mortality from all causes and hospitalization due to decompensation). The present study, therefore, will evaluate the effect of outpatient fluid restriction on levels of NT-proBNP in patients who remain with signs of congestion based on pulmonary ultrasound at the bedside during hospital discharge.

Enrollment

75 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Hospital admission for primary diagnosis of acutely decompensated heart failure, regardless of etiology, according to the criteria of the American College of Cardiology;
  • Diagnosis on echocardiography of heart failure with reduced ejection fraction (<40%);
  • Presence of pulmonary congestion defined as at least 2 pulmonary fields with more than 3 B lines in each field on pulmonary ultrasound at the time of hospital discharge.

Exclusion criteria

  • Pulmonary fibrosis or other severe disease that changes the image acquisition (significant pleural effusion, severe pulmonary emphysema, previous pneumectomy or lobectomy, primary or metastatic lung cancer, breast implants);
  • Pregnancy;
  • Dialysis renal failure patient;
  • Factors that could hinder follow-up (not returning to the outpatient clinic of Hospital de Clínicas);
  • Disability or refusing to understand and adhere to the protocol;
  • Refusal to sign consent form.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

75 participants in 2 patient groups

Fluid restriction
Experimental group
Description:
Prescription to ingest approximately 20 ml / kg of ideal weight.
Treatment:
Behavioral: Fluid restriction
Control
No Intervention group
Description:
Prescription to ingest approximately 30 ml / kg of ideal weight, considered a normal amount of daily water intake.

Trial contacts and locations

1

Loading...

Central trial contact

Marcelo Nicola Branchi

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems